Allen Rossetti Chung
Radiation Oncology · Providence, RINPI 1669834552
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $301 of the $349 with a category attached, or 86.3%. Novocure Inc. accounts for 65.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $229 and has fallen 77.6% since, to $51 in 2025.
Across 7 payments — averaging $49.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$229
- Myovant Sciences Inc.$48
- Bioprotect Medical, Inc.$32
- Sanofi$21
- Pfizer$19
What the payments were for
- Food & beverage$30186%
- Education$4814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 2 | $229 |
| Myovant Sciences Inc. | 2 | $48 |
| Bioprotect Medical, Inc. | 1 | $32 |
| Sanofi | 1 | $21 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$111
How this compares
$349 in reported general payments places this provider in the 65th percentile of 26 radiation oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Silver Sulfadiazine | 16 | $192 |
| Dexamethasone | 19 | $121 |
| Tamsulosin Hcl | 15 | $118 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Providence
- David WazerProvidence$10K
- Sana RaoofProvidence$4K
- Brijal DesaiProvidence$2K
- Nicklas OldenburgProvidence$699
- Timothy ShafmanProvidence$594
- Thomas DipetrilloProvidence$451
- Andrew KopeckyProvidence$322
- Jessica YanceyProvidence$259
- John CoenProvidence$229
- Esther YuProvidence$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.